Table 2.
Population mean drug dose by BMI group
| Drug and study | No. patients/no. courses | Normal, mg/m2 | Underweight, mg/m2 | Underweight, % change* | At risk of overweight, mg/m2 | At risk of overweight, % change* | Overweight, mg/m2 | Overweight, % change* | P |
|---|---|---|---|---|---|---|---|---|---|
| High-dose methotrexate | |||||||||
| TXII fixed dose | 86/393 | 1501 | 1506 | 0 | 1489 | -1 | 1498 | 0 | .47 |
| TXII targeted | 85/397 | 2041 | 2065 | 1 | 2215 | 9 | 2109 | 3 | .53 |
| TXIIIB | 230/2174 | 1960 | 1979 | 1 | 1944 | -1 | 1929 | -2 | .003 |
| TXIV low | 22/118 | 2427 | 2409 | -1 | 2406 | -1 | 2368 | -2 | .007 |
| TXIV high | 26/138 | 4941 | 4773 | -3 | 4996 | 1 | 4944 | 0 | .32 |
| Etoposide | |||||||||
| TXIIIB | 113/184 | 299 | 291 | -3 | 299 | 0 | 301 | 1 | .38 |
| Cytarabine | |||||||||
| TXII fixed dose | |||||||||
| D 1 | 86/394 | 299 | 298 | 0 | 299 | 0 | 293 | -2 | .16 |
| D 3 | 67/274 | 299 | 296 | -1 | 296 | -1 | 291 | -3 | .048 |
| D 5 | 11/16 | 307 | NA | NA | 300 | -2 | NA | NA | .15 |
| TXII targeted | |||||||||
| D 1 | 83/396 | 428 | 399 | -7 | 418 | -2 | 412 | -4 | .88 |
| D 3 | 65/253 | 419 | 415 | -1 | 418 | 0 | 435 | 4 | .99 |
| D 5 | 12/19 | 285 | 299 | 5 | 317 | 11 | 347 | 22 | .72 |
| Teniposide | |||||||||
| TXII fixed dose | |||||||||
| D 1 | 85/391 | 201 | 198 | -1 | 199 | -1 | 196 | -2 | .048 |
| D 3 | 67/272 | 201 | 196 | -2 | 199 | -1 | 195 | -3 | .032 |
| D 5 | 11/16 | 202 | NA | NA | 201 | 0 | NA | NA | .8 |
| TXII targeted | |||||||||
| D 1 | 83/397 | 256 | 244 | -5 | 266 | 4 | 254 | -1 | .89 |
| D 3 | 65/253 | 281 | 259 | -8 | 285 | 1 | 271 | -4 | .89 |
| D 5 | 12/19 | 296 | 230 | -23 | 377 | 27 | 237 | -20 | .51 |
| Mercaptopurine | |||||||||
| TXII | 169/653 | 75.4 | 76.2 | 1 | 76.1 | 1 | 76.7 | 2 | .74 |
NA indicates no data available for group.
*
Relative to the normal-weight group.